Maturation inhibitors as new antiretroviral agents

Journal of HIV Therapy

Volumn 13, Issue 4, 2008, Pages 79-82

  Richards, John ^a   Mccallister, Scott ^a  

^a Panacos Pharmaceuticals   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BEVIRIMAT; ENFUVIRTIDE; GAG PROTEIN; MARAVIROC; PLACEBO; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; YK FH 312; 3-O-(3',3'-DIMETHYLSUCCINYL)BETULINIC ACID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; SUCCINIC ACID DERIVATIVE; TRITERPENE;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PROTEIN PROCESSING; UNSPECIFIED SIDE EFFECT; VIRUS ASSEMBLY; VIRUS REPLICATION; DOSE RESPONSE; DRUG ANTAGONISM; HUMAN IMMUNODEFICIENCY VIRUS; PHASE 2 CLINICAL TRIAL; PHYSIOLOGY; REVIEW; VIROLOGY;

ANTI-HIV AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV; HIV CORE PROTEIN P24; HIV INFECTIONS; HUMANS; SUCCINATES; TRITERPENES;

EID: 65649087539     PISSN: 14620308     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. UNAIDS. Joint United Nations Programme on HIV/AIDS. AIDS Epidemic 2008 Update: Report on the Global AIDS Epidemic. Geneva, Switzerland, 2008.
2. Pillay D, Taylor S, Richman DD. Incidence and impact of resistance against approved antiretroviral drugs. Rev Med Virol, 2000, 10, 231-253.
3. Loveday C. International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr, 2001, 26 Suppl 1, S10-S24.
4. Harris M, Montaner JSG. Management of HIV-infected patients with multidrug-resistant virus. Curr HIV/AIDS Rep, 2004, 1, 116-121.
5. Gallant JE. Approach to the treatment-experienced patient. Infect Dis Clin North Am, 2007, 21, 85-102.
6. Anderson AML, Bartlett JA. Changing antiretroviral therapy in the setting of virologic relapse: review of the current literature. Curr HIV/AIDS Rep, 2006, 3, 79-85.
7. Perno CF, Moyle G, Tsoukas C et al. Overcoming resistance to existing therapies in HIV-infected patients: the role of new antiretroviral drugs. J Med Virol, 2008, 80, 565-576.
8. Adamson C, Ablan S, Boeras I et al. In vitro resistance to HIV-1 maturation inhibitor PA-457 (bevirimat). J Virol, 2006, 80, 10957-10971.
9. Li F, Goila-Gaur R, Salzwedel K et al. PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci U S A, 2003, 100, 3555-3560.
10. Zhou J, Yuan X, Dismuke D et al. Small-molecule inhibition of HIV-1 replication by specific targeting of the final step of virion maturation. J Virol, 2004, 78, 922-929.
11. Aiken C, Chen C. Betulinic acid derivatives as HIV-1 antivirals. Trends Mol Med, 2005, 11, 31-36.
12. Kanamoto T, Kashiwada Y, Kanbara K et al. Anti-HIV activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation. Antimicrob Agents Chemother, 2001, 45, 1225-1230.
13. Li F, Wild C. HIV-1 assembly and budding as targets for drug discovery. Curr Opin Invest Drugs, 2005, 6, 148-154.
14. Pettit S, Lindquist J, Kaplan A, Swanstrom R. Processing sites in HIV-1 Gag-Pro-Pol precursor are cleaved by the viral protease at different rates. Retrovirology, 2005, 2, 66.
15. Pettit S, Clemente J, Jeung J et al. Ordered processing of the HIV-1 GagPol precursor is influenced by the context of the embedded viral protease. J Virol, 2005, 79, 10601-10607.
16. Pettit S, Henderson G, Schiffer C, Swanstrom R. Replacement of the P1 amino acid of HIV-1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease. J Virol, 2002, 76, 10226-10233.
17. Pettit S, Moody M, Wehbie R et al. The p2 domain of HIV-1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J Virol, 1994, 68, 8017-8027.
18. Wiegers K, Rutter G, Kottler H et al. Sequential steps in HIV particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J Virol, 1998, 72, 2846-2854.
19. Kräusslich H-G, Fäcke M, Heuser A-M et al. The spacer peptide between HIV capsid and nucleocapsid proteins is essential for ordered assembly and viral infectivity. J Virol, 1995, 69, 3407-3419.
20. Salzwedel K, Martin DE, Sakalian M. Maturation inhibitors: a new therapeutic class targets the virus structure. AIDS Rev, 2007, 9, 162-172.
21. Stoddart CA, Joshi P, Sloan B et al. Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv Mice. PL0S ONE, 2007, 2, e1251.
22. Choe S, Feng Y, Limoli K et al. Measurement of maturation inhibitor susceptibility using the PhenoSense HIV assay. 15th Conference on Retroviruses and Opportunistic Infections. Boston, February 2008. Abstr 880.
23. Beatty G, Jacobson J, Lalezari J et al. Safety and antiviral activity of PA-457, the first-in-class maturation inhibitor, in a 10-day monotherapy study in HIV-1 infected patients. 45th ICAAC. Washington DC, December 2005. Abstr LB-27.
24. Smith PF, Ogundele A, Forrest A et al. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics o single-dose 3-O-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother, 2007, 51, 3574.3581.
25. Martin DE, Blum R, Wilton J et al. Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers Antimicrob. Agents Chemother, 2007, 51, 3063-3066.
26. McCallister S, Lalezari J, Richmond G et al. HIV-1 Gag polymorphisms determine treatment response to bevirimat (PA-457). XVII International HIV Drug Resistance Workshop, Sitges, Spain, June 2008. Abstr 8.
27. Hamy F, Louvel S, Salzwedel K et al. New phenotyping assay demonstrates role of Gag-SP1 polymorphisms in HIV-1 sensitivity to the maturation inhibitor bevirimat. XVII International HIV Drug Resistance Workshop, Sitges, Spain, June 2008. Abstr 30.
28. Van Baelen K, Salzwedel K, De Wolf H et al. HIV-1 susceptibility to the maturation inhibitor bevirimat is modulated by natural polymorphisms at positions 369-371 in Gag SP1. XVII International HIV Drug Resistance Workshop, Sitges, Spain, June 2008. Abstr 28.
29. Salzwedel K, Reddick M, Matallana C et al. Role of Gag polymorphisms in HIV-1 sensitivity to the maturation inhibitor bevirimat. XVII International HIV Drug Resistance Workshop, Sitges, Spain, June 2008, Abstract 29.
30. Clevenbergh P, Durant J, Chaillou S, Dellamonica P. HIV drug resistance and insufficient drug plasma levels as factors determining antiretroviral treatment failure. AIDS Rev, 1999, 1, 156-166.
31. Feinberg M. Hidden dangers of incompletely suppressive antiretroviral therapy. Lancet, 1997, 349, 1408-1409.
32. Mellors JW, Rinaldo, Jr CR, Gupta P et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science, 1996, 272, 1167-1170.
33. Richman, DD, Morton SC, Wrin T et al. The prevalence of antiretroviral drug resistance in the United States. AIDS, 2004, 18, 1393-1401.
34. LaBonte J, Lebbos J, Kirkpatrick P. Enfuvirtide. Nat Rev Drug Discov, 2003, 2, 345-346.
35. Wensing AM, van de Vijver, Angarano G et al. Prevalence of drugresistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis, 2005, 192, 1501.